A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population
- 6 April 2009
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 27 (16), 2251-2257
- https://doi.org/10.1016/j.vaccine.2009.02.024
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18–60 years of age) with chronic diseases who are at risk of post-influenza complicationsVaccine, 2007
- The Boomers Are Coming: A Total Cost of Care Model of The Impact of Population Aging on The Cost of Chronic Conditions in The United StatesDisease Management, 2007
- Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trialThe Lancet, 2006
- The Boomers Are Coming: A Total Cost of Care Model of the Impact of Population Aging on Health Care Costs in the United States by Major Practice CategoryHealth Services Research, 2006
- Vaccines for preventing influenza in the elderlyPublished by Wiley ,2005
- The unmet need in the elderly: Designing new influenza vaccines for older adultsVaccine, 2005
- InfluenzaThe Lancet, 2003
- Toward Consistency in Cost-Utility AnalysesMedical Care, 1998
- Clinical effectiveness of influenza vaccination in ManitobaPublished by American Medical Association (AMA) ,1993
- The utility of different health states as perceived by the general publicJournal of Chronic Diseases, 1978